FierceBiotech

Roche celebrates Pharma Day by buying Regor's CDK inhibitors, regenerative med-focused AntlerA

Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients ...
ascopubs.org

CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer

Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? Antiestrogen therapy remains the targeted therapy par ...
ascopubs.org

Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.

TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ...
Nature

The history and future of targeting cyclin-dependent kinases in cancer therapy

Cyclin-dependant kinase 4 (CDK4) and CDK6 phosphorylate the tumour suppressor retinoblastoma protein (RB), resulting in the release of the E2F transcription factor and progression through the cell ...